Triamterene may preserve lymphocyte magnesium and potassium in patients with congestive heart failure.
Electrolyte abnormalities are a frequent and potentially hazardous complication in the treatment of patients with congestive heart failure. Medical treatment with diuretics and/or digitalis, as well as neurohumoral activation most likely initiated by the compromised cardiac function, contributes to this alteration. The addition of potassium- and magnesium-sparing diuretics (triamterence, amiloride) to therapy with frusemide or hydrochlorothiazide is of possible value in preventing intracellular electrolyte abnormalities.
Schwinger
R H
RH
Medizinische Klinik I (Kardiologie), Krankenhaus München-Bogenhausen, Germany.
Antoni
D H
DH
D000368:Aged; D000369:Aged, 80 and over; D004077:Digoxin / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000378:metabolism; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007424:Intracellular Fluid / Q000737:chemistry; D008214:Lymphocytes / Q000378:metabolism*; D008274:Magnesium / Q000097:blood*; D008875:Middle Aged; D011188:Potassium / Q000097:blood*; D014223:Triamterene / Q000494:pharmacology*
D006852:Hydrochlorothiazide; D004077:Digoxin; D005665:Furosemide; D008274:Magnesium; D011188:Potassium; D014223:Triamterene